Entero Therapeutics (NASDAQ:ENTO) Shares Up 6.3% – What’s Next?

Shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) rose 6.3% during trading on Monday . The company traded as high as $4.72 and last traded at $3.87. Approximately 618,995 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 2,798,922 shares. The stock had previously closed at $3.64.

Entero Therapeutics Trading Up 6.3%

The company has a market capitalization of $6.15 million, a P/E ratio of -2.29 and a beta of 1.19. The business has a 50 day moving average price of $2.44 and a 200 day moving average price of $2.96.

Hedge Funds Weigh In On Entero Therapeutics

An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC acquired a new stake in Entero Therapeutics, Inc. (NASDAQ:ENTO) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned 0.74% of Entero Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 12.30% of the company’s stock.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical?stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility?related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.